

PROVINCIAL FUNDING SUMMARY

Regorafenib (Stivarga) for Gastrointestinal Stromal Tumour (GIST)

pERC Recommendation: Recommends with Conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: May 20, 2014

This information is current as of May 25, 2015.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Feb 1, 2015	Advanced gastrointestinal stromal tumour with disease progression on or intolerance to imatinib and sunitinib. <ul style="list-style-type: none"> ▫ Not amenable to surgery or other local therapy. ▫ No major surgery within 14 days of administration of therapy
AB	Funded	Mar 30, 2015	Regorafenib in the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumours (GIST) who have had disease progression on or intolerance to imatinib and sunitinib, in patients with ECOG of 0 or 1
SK	Funded	Sep 15, 2014	Treatment of patients with metastatic and/or unresectable GIST who have had disease progression on, or intolerance to, Imatinib and Sunitinib, and have an ECOG performance status of 0 or 1
MB	Funded	Jan 19, 2015	For the treatment of patients with metastatic or unresectable gastrointestinal stromal tumor (GIST) and have had disease progression on or intolerance to imatinib and sunitinib and have an ECOG performance status of 0 to 1.
ON	Funded	Sep 9, 2014	Initial requests: For patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who have had disease progression on, or intolerance to, imatinib and sunitinib Dosage: 160 mg once daily for 3 weeks followed by 1 week of no therapy to comprise a cycle of 4 weeks. Treatment should continue as long as benefit is observed or until unacceptable toxicity occurs. Approval Period: 6 months Renewal requests: Patient continues to derive benefit from therapy Approval Period: 6 months

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NS	Funded	Dec 29, 2014	For patients with metastatic and/or unresectable GIST who have had disease progression on, or intolerance to, imatinib and sunitinib and have an ECOG performance status of 0-1.
NB	Funded	Nov 21, 2014	<p>For the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who have had disease progression on, or intolerance to, imatinib and sunitinib, and who have an ECOG performance status of 0 or 1.</p> <p>Renewal Criteria: Written confirmation that the patient continues to benefit from therapy.</p> <p>Clinical Note: Recommended dose: 160mg once daily (3 weeks on, 1 week off).</p> <p>Claim Notes:</p> <ul style="list-style-type: none"> • Initial approval duration: 6 months • Renewal approval duration: 6 months
NL	Funded	Oct 1, 2014	For patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who have had disease progression on, or intolerance to, imatinib and sunitinib; AND patient has ECOG \leq 1.
PEI	Under provincial consideration*		

*Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pricing Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.